Business
BetterLife Announces Debt Settlements
VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders, announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shar
About this update from Betterlife Pharma Inc.
[{"type":"image","alt":"BetterLife Pharma Inc.","displaySize":"","headline":null,"caption":"BetterLife Pharma Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":286,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/8ec617ad108ee4b453638b3289aecdcf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.eZRgbrXhIvBBD2d8LUGaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8ec617ad108ee4b453638b3289aecdcf","width":286,"height":79}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders, announces that it has issued 14,999,303 common shares pursuant to the settlement of accounts payable and amounts due to directors and officers totaling $1,499,930. The common shares issued will be subject to a four month hold period pursuant to applicable Canadian securities laws. The Company’s officers and directors settled $1.03 million in amounts owed for a total of 10,308,039 common shares.","length":735,"tagName":"p"},{"type":"text","content":"The Company also issued 250,000 common shares pursuant to the exercise of 250,000 share purchase warrants for gross proceeds of $25,000.","length":136,"tagName":"p"},{"type":"text","content":"About BetterLife Pharma ","length":23,"tagName":"p"},{"type":"text","content":"BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.","length":204,"tagName":"p"},{"type":"text","content":"BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic neuroplastogen in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.","length":469,"tagName":"p"},{"type":"text",...